Checked.be
Active
BE 0766.337.513Private limited company
JMJ PHARMA
Rue Jules Hagnoul(O) 1 ·1350 Orp-Jauche, Belgium· 5 yrs active
Sector: Retail sale of pharmaceutical products
(47730)
Conclusion
The computed 12-month bankruptcy probability of JMJ PHARMA is 2.1% (moderate). The 2024 annual accounts show equity of €110k and a net result of €14k. Equity is growing by ~3.2% per year across the filed fiscal years. Its solvency ranks better than 24% of 6591 sector peers (fiscal year 2024). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 4 annual accounts.
Key figures
| Equity | €110k |
| Net result | €14k |
| Staff (FTE) | 1.7 |
| Better than sector | 24% |
Financial profile
61
/ 100
Strong profile, led by stability.
All 5 axes are computed from data Checked has read.
Health
66
Profitability
64
Solvency
27
Growth
55
Stability
94
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
More than 3 years active
Founded in 2021, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
66
/ 100
Healthy
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€7k
estimate, not credit advice
Score history
76
2021
37
2022
59
2023
66
2024
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 1.37 (≥ 1.0)
+5
Quick ratio
Quick ratio 0.42 (< 0.6)
-5
Leverage
Debt/equity 7.22 (> 3.0)
-10
Profitability
ROE 13% (≥ 10%)
+10
Interest coverage
Interest coverage 7.9× (≥ 3×)
+8
Profit trend
Net profit up YoY
+5
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.
Financial overview
Annual accounts filed on 29-07-2025 with the NBB · fiscal year 2024 · full schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~3.2%/year over 4 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2024 · NACE 47, Retail trade · compared within the same schema type (full schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 12.2% | 32.5% | |
| Net result | €14k | €32k | |
| Equity | €110k | €299k | |
| Gross operating margin | €175k | €265k | |
| Staff costs | €82k | €239k |
€1,000k
+40.6%
21-24
€90k
+2.5%
21-24
€14k
+58.2%
21-24
€77k
+2.6%
21-24
€901k
-5.3%
21-24
€110k
+14.7%
21-24
€63k
+3.2%
21-24
2
-29.2%
21-24
€82k
-31.7%
21-24
€2k
+478.1%
21-24
€792k
-7.5%
21-24
€170k
+6.6%
21-24
€622k
-10.8%
21-24
1.37
-0.9%
21-24
0.42
+16.0%
21-24
12.2%
+21.1%
21-24
7.22
-19.4%
21-24
12.8%
+37.9%
21-24
1.6%
+67.0%
21-24
-3.5%
-
21-24
4.3%
-61.1%
21-24
7.90
+14.2%
21-24
Figures by fiscal year and ratios
Change versus the prior fiscal year, coloured by direction (green = favourable).
| Fiscal year | 2024 Δ | 2023 Δ | 2022 Δ | 2021 Δ |
|---|---|---|---|---|
| Deposit | full schema | micro schema | micro schema | micro schema |
| Revenue | - | - | +40.6% | - |
| EBITDA | +2.5% | +106.8% | -45.2% | - |
| Net profit | +58.2% | - | - | - |
| Cash flow | +2.6% | +141.0% | -50.7% | - |
| Staff costs | -31.7% | -13.8% | +117.1% | - |
| Income taxes | +478.1% | - | - | - |
| Dividends | - | - | - | - |
| Total assets | -5.3% | -8.6% | -8.7% | - |
| Equity | +14.7% | +10.2% | -28.6% | - |
| Debt | -7.5% | -10.4% | -6.3% | - |
| of which ≤ 1y | +6.6% | -13.4% | +6.7% | - |
| of which > 1y | -10.8% | -9.7% | -8.7% | - |
| Working capital | +3.2% | -0.6% | -44.2% | - |
| Employees (FTE) | -29.2% | -14.3% | +3.7% | - |
Note: these years are not on the same basis. The filed schemas differ (full schema, micro schema), so the columns are not directly comparable.
Ratios (computed)
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Current ratio | 1.37 | 1.38 | 1.33 | 1.64 |
| Quick ratio | 0.42 | 0.36 | 0.47 | 0.74 |
| Working capital ratio | 7.0% | 6.4% | 5.9% | 9.6% |
| Solvency | 12.2% | 10.1% | 8.3% | 10.7% |
| Debt / equity | 7.22 | 8.95 | 11.00 | 8.38 |
| Long-term debt ratio | 5.67 | 7.28 | 8.88 | 6.95 |
| Interest coverage | 7.90 | 6.92 | 3.67 | 8.65 |
| Gross margin | - | - | 17.4% | 19.5% |
| Net margin | - | - | -3.5% | 3.0% |
| ROA | 1.6% | 0.9% | -3.3% | 1.9% |
| ROE | 12.8% | 9.3% | -40.1% | 17.8% |
| EBITDA margin | - | - | 4.3% | 11.0% |
| Days sales outstanding | - | - | 20d | 23d |
| Days payable outstanding | - | - | 35d | 46d |
| Inventory turnover | - | - | 5.17 | 3.69 |
| Days inventory (DSI) | - | - | 71d | 99d |
Balance-sheet composition 2024
Full annual accounts (26 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €901k | €952k | €1.04M | €1.14M |
| Fixed assets | 21/28 | €668k | €732k | €797k | €858k |
| Intangible fixed assets | 21 | €304k | €352k | €400k | €448k |
| Tangible fixed assets | 22/27 | €364k | €379k | €396k | €410k |
| Financial fixed assets | 28 | €349 | €349 | €849 | €349 |
| Current assets | 29/58 | €233k | €220k | €245k | €282k |
| Stocks & contracts in progress | 3 | €162k | €163k | €160k | €155k |
| Amounts receivable within one year | 40/41 | €62k | €48k | €54k | €44k |
| Cash & bank | 54/58 | €9k | €9k | €31k | €81k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €901k | €952k | €1.04M | €1.14M |
| Equity | 10/15 | €110k | €96k | €87k | €122k |
| Contributions / capital | 10/11 | €100k | €100k | €100k | €100k |
| Accumulated profits (losses) | 14 | €10k | €-4k | €-13k | €22k |
| Amounts payable | 17/49 | €792k | €856k | €955k | €1.02M |
| Amounts payable after one year | 17 | €622k | €697k | €771k | €845k |
| Amounts payable within one year | 42/48 | €170k | €159k | €184k | €172k |
| Trade debts payable within one year | 44 | €77k | €66k | €80k | €73k |
| Income statement | |||||
| Turnover | 70 | - | - | €1,000k | €711k |
| Gross operating margin | 9900 | €175k | €209k | €183k | €142k |
| Operating result | 9901 | €27k | €22k | €-23k | €36k |
| Financial income | 75 | €64 | €33 | €142 | €10 |
| Financial charges | 65 | €11k | €13k | €12k | €9k |
| Result before taxes | 9903 | €16k | €9k | €-35k | €27k |
| Income taxes | 67/77 | €2k | €332 | - | €6k |
| Net result for the period | 9904 | €14k | €9k | €-35k | €22k |
| Result to be appropriated | 9905 | €14k | €9k | €-35k | €22k |
Legal Structure
| NACE primary | Retail sale of pharmaceutical products(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 02-04-2021 |
| Status | Active |
| Postal code | 1350 |
Establishment units
Pharmacie Fraiture-Joos
since 20212.316.032.673
Real-estate footprint
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25082B0409/00P000 | Wallonia | 59 m² | 1 · 55 m² | 10.7 m · 3 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
2025
29-07
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Equity above €100kEq €110k ▲14.7%
2 profitable years in a row build equity to €110k.
11-06
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Back to profitnet €9k
Net result €9k after one loss-making year.
02-06
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Weakest financial yearnet €-35k ▼261%
Net result drops to €-35k, the lowest in the series; recovery starts the following year.
29-06
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Retail sale of pharmaceutical products47730
Names & trade names
| Legal nameFR | JMJ PHARMA |
| Trade nameFR | Pharmacie Fraiture-Joos |
Similar companies
INGRID LUYTEN
BE 0627.936.923 · Turnhout
APONE
BE 0805.241.045 · Hemiksem
Apotheek Tereken
BE 0426.318.958 · Sint-Niklaas
APOTHEEK REYSKENS
BE 0459.506.123 · Gingelom
STRAGIER
BE 0443.120.150 · Ath